Amneal Pharmaceuticals Inc SEC Filings

BOYER ANDREW S reported acquisition or exercise transactions in this Form 4 filing.

Amneal Pharmaceuticals Executive Vice President Andrew S. Boyer reported awards of 65,359 restricted stock units and 65,359 performance-based restricted stock units. Each unit represents a contingent right to receive one share of Class A common stock if vesting conditions are met.

The time-based restricted stock units vest in four equal annual installments beginning on March 2, 2027. The performance-based units are tied to average closing price targets over a three-year period ending February 28, 2029, with payout ranging from 0% to 200% of a 65,359-share target and a maximum of 65,359 shares issuable under the award.

Amneal Pharmaceuticals, Inc. outlines its business and key developments as a diversified global biopharmaceutical company with three segments: Affordable Medicines, Specialty, and AvKARE. Affordable Medicines spans more than 280 generic and biosimilar product families, including injectables, respiratory products, and oncology biosimilars.

The company highlights new collaborations with ApiJect for blow-fill-seal injectables, Metsera (now tied to Pfizer) for weight-loss medicines and Indian manufacturing, and Kashiv for complex injectables and biosimilars. It also licenses IPX203 (CREXONT®) rights to Zambon in Europe and Knight in Canada and Latin America, and markets ONGENTYS® under a BIAL agreement it plans to terminate in 2028.

Recent approvals include U.S. FDA clearance for respiratory generics QVAR® and ProAir® HFA equivalents and denosumab biosimilars Boncresa™ and Oziltus™, bringing its U.S. biosimilar count to five. In Specialty, Amneal launched CREXONT® for Parkinson’s disease and Brekiya® autoinjector for migraine and cluster headache, while RYTARY® faces generic competition.

The filing stresses regulatory, pricing, and reimbursement risks, including U.S. healthcare reform and Medicare negotiation under the Inflation Reduction Act. Customer concentration is significant: four large customers account for about 71% of consolidated net revenue. As of June 30, 2025, aggregate market value of non‑affiliate common stock was approximately $1.7 billion, and as of February 13, 2026, Class A common stock outstanding totaled 314,629,101 shares.

Amneal Pharmaceuticals reported strong fourth quarter and full-year 2025 results, returning solidly to profitability and increasing cash generation. Q4 2025 net revenue rose 11% to $814 million, with GAAP net income of $35 million and diluted EPS of $0.11, while adjusted EBITDA reached $175 million and adjusted diluted EPS was $0.21.

For 2025, net revenue grew to $3.02 billion from $2.79 billion, and net income attributable to Amneal improved to $72 million from a $117 million loss, driven by higher revenue, better gross profit and lower expenses. Adjusted EBITDA increased 10% to $688 million and adjusted diluted EPS rose to $0.83. Specialty revenue grew 19%, Affordable Medicines 4%, and AvKARE 12%.

For 2026, Amneal guides to net revenue of $3.05–$3.15 billion, adjusted EBITDA of $720–$760 million, adjusted diluted EPS of $0.93–$1.03, and operating cash flow of $325–$375 million. Net debt was $2.41 billion at December 31, 2025, implying net leverage of 3.5x, down from 3.9x a year earlier.

Amneal Pharmaceuticals, Inc. amended its term loan credit agreement through a repricing transaction. Existing term loans held by consenting lenders were converted on a cashless basis into new term loans totaling $1,960,076,527.50, and the company added a new term loan of $134,673,472.50 to refinance remaining old loans at par.

The amendment lowers the interest rate margin on the new term loans by 50 basis points to 2.00% for base rate loans and 3.00% for loans based on the secured overnight financing rate, while keeping the August 1, 2032 maturity date unchanged. Amneal estimates approximately $11 million in annualized cash interest savings from this repricing, improving its ongoing financing costs.

Amneal Pharmaceuticals is moving ahead with a nationwide agreement to settle a substantial majority of opioids-related claims brought by states and local subdivisions. The settlement becomes effective on January 29, 2026.

Under the agreement, Amneal will pay participating states and subdivisions $88.5 million in cash and provide up to $177.4 million in naloxone nasal spray, valued at $125 per twin pack, to help treat opioid overdoses. Instead of product, settling parties may elect to receive 25% of the naloxone value, up to $44.4 million in additional cash during the final four years of the ten‑year payment term, which would bring the total cash commitment up to $132.9 million.

Amneal Pharmaceuticals plans to tell investors it expects to meet or exceed its previously issued 2025 full-year financial guidance. The company continues to target net revenue of $3.0 billion to $3.1 billion, adjusted EBITDA of $675 million to $685 million, adjusted diluted EPS of $0.75 to $0.80, operating cash flow of $300 million to $330 million, and capital expenditures of about $100 million net of a $20 million alliance contribution.

Amneal also estimates its net leverage as of December 31, 2025 to be about 3.6x, improved from 3.9x a year earlier. The outlook relies on management’s assumptions about prescription trends, pricing, product launches, restructuring impacts and strategy execution, and uses several non-GAAP measures such as adjusted EBITDA, adjusted diluted EPS and net leverage, which exclude items like acquisition and restructuring costs, legal charges and certain non-cash expenses.

Amneal Pharmaceuticals, Inc. filed a Form 4 showing a share sale by one of its directors. On 11/17/2025, the reporting person sold 50,000 shares of Amneal Class A common stock in an open-market transaction coded "S" for sale. The weighted average sale price was $11.72 per share, with individual trades executed between $11.70 and $11.75 per share.

After this transaction, the reporting person beneficially owns 291,029 shares of Amneal Class A common stock in direct ownership form. The filing notes that full details of the individual trade prices within the reported range are available upon request.

Amneal Pharmaceuticals, Inc. (AMRX) reported insider activity by its Executive Vice President. On November 12, 2025, the officer exercised stock options for 36,331 and 95,525 shares at an exercise price of $2.75 per share and sold 131,856 Class A shares at a $11.92 weighted average price.

The sale occurred across multiple trades between $11.85 and $12.02 per share. Following these transactions, the reporting person directly beneficially owned 146,403 shares. The reported option grants (fully vested) show 0 derivative securities remaining after exercise, with prior expirations listed as May 7, 2028 and March 1, 2029.

Amneal Pharmaceuticals (AMRX) reported Q3 2025 results. Net revenue was $784.5 million, up from $702.5 million a year ago. Operating income was $70.3 million versus $88.8 million. Net income attributable to Amneal was $2.4 million, or $0.01 per diluted share.

Performance by segment in Q3: Affordable Medicines $460.7 million, Specialty $125.2 million, and AvKARE $198.5 million. Year to date, net revenue reached $2.20 billion and operating income was $282.1 million, with diluted EPS of $0.11.

Results reflect a $31.4 million loss on refinancing, a $22.8 million intangible asset impairment tied to an FDA complete response letter dated July 22, 2025, and a tax benefit from the One Big Beautiful Bill Act that reduced current income tax liabilities by $23.5 million in Q3. Cash from operating activities for the first nine months was $209.7 million, with cash and cash equivalents of $201.2 million at September 30, 2025. Long‑term debt, net, was $2.57 billion.